Investigators found patients receiving chemotherapy had a greater risk of a secondary primary malignancy (SPM) compared with those treated with targeted therapies or those whose chronic lymphocytic leukemia (CLL) was left untreated.
A panel of expert oncologists explore novel therapies using monoclonal antibodies designed to target amyloid deposit, highlighting key data from the VITAL study.